Dispatch Bio’s virus therapy DV-10 enters phase 1.
ApexOnco Front Page
Recent articles
The QCS assay for TROP2 is being implemented more broadly, at the cost of further readout delays.
The company quietly deprioritises AlphaMedix.
RMC-5127 becomes the company’s fourth clinical project.
The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
Tecvayli and Hernexeos might get speedy approval decisions.
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
The line-up is revealed to include Merck & Co and J&J itself.
